Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.136579010.3389/fphar.2024.1365790PharmacologyCorrectionCorrigendum: Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectivesMitra et al.10.3389/fphar.2024.1365790MitraSicon1†AnandUttpal2†GhoraiMimosa3VellingiriBalachandar4JhaNiraj Kumar1BehlTapan5KumarManoj6Radha7ShekhawatMahipal S.8ProćkówJarosław9*DeyAbhijit3*1Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India2CytoGene Research & Development LLP, Lucknow, Uttar Pradesh, India3Department of Life Sciences, Presidency University, Kolkata, India4Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, India5Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Chandigarh, India6Chemical and Biochemical Processing Division, ICAR-Central Institute for Research on Cotton Technology, Mumbai, India7School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, India8Department of Plant Biology and Biotechnology, Kanchi Mamunivar Government Institute for Postgraduate Studies and Research, Puducherry, India9Department of Plant Biology, Institute of Environmental Biology, Wrocław University of Environmental and Life Sciences, Wrocław, Poland
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Unravelling the therapeutic potential of botanicals against chronic obstructive pulmonary disease (COPD): molecular insights and future perspectives by Mitra S, Anand U, Ghorai M, Vellingiri B, Jha NK, Behl T, Kumar M, Radha, Shekhawat MS, Proćków J and Dey A (2022). Front. Pharmacol. 13:824132. doi: 10.3389/fphar.2022.824132lungsinflammationalternative therapymedicinal plantsCOVID-19COPDclinical efficacyplant-based formulationsection-at-acceptanceRespiratory Pharmacology
In the published article, there was an error in the Affiliation information about Uttpal Anand [2]. Instead of “Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,” it should be “CytoGene Research & Development LLP, Lucknow, Uttar Pradesh, India.”
As a result of the change in affiliation above, the Conflict of Interest statement must be amended to the following.
Conflict of interest
Author UA was employed by the company CytoGene Research & Development LLP.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.